Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cibus US LLC has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners and 2 art units, so counsel must coordinate across separate technical examination channels and examiner-specific response requirements.
STOCKDALE, JESSICA NICOLE is the busiest examiner, with 1 pending matter. This examiner handles one active matter, making it important to preserve a separate strategy for the other pending action.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOCKDALE, JESSICA NICOLE | 1 | 51.4% | +33.3% |
| BYRNES, DAVID R | 1 | 78.2% | +20.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248017 | GRAFTED PLANT FOR DELIVERY OF GENOME EDITING REAGENTS | STOCKDALE, JESSICA NICOLE | 12d |
| 17780792 | TAL-EFFECTOR NUCLEASES FOR GENE EDITING | BYRNES, DAVID R | 30d |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18248017 | GRAFTED PLANT FOR DELIVERY OF GENOME EDITING REAGENTS | STOCKDALE, JESSICA NICOLE | 1663 | §103 | Final Rejection | 12d | Pending | Apr 05, 2023 |
| 17780792 | TAL-EFFECTOR NUCLEASES FOR GENE EDITING | BYRNES, DAVID R | 1662 | §112 | Final Rejection | 30d | Pending | May 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCibus US LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jessica Nicole Stockdale has the most, with 1 of Cibus US LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
